![]() To Heart 2 is, as all of the aforementioned titles aswell as many I've not mentioned here, one of the most predictable animes ever produced, but if it wasn't predictable then maybe something original could happen and we wouldn't want that! Oh no we wouldn't would we Ken-chan? Sometimes it isn't a robot girl either, sometimes it's an alien, or maybe even a mermaid! There is always a demand for these kinds of anime, even the fanboys know that this is just like the 30 almost axactly similar animes they've seen before, but since the art is slightly different, the characters are slightly different, the guy attends highschool instead of middle school or his name is Ken-chan instead of Hiroyuki-chan it becomes worth watching. Why do they make all of these generic fanboy animes one can ask oneself? The answer is simple! For the fanboys. It is thrown into the same bunch of quality productions such as To Heart, To Heart remember my memories, Kono Aozora ni yakusoku wo, Amaenaide yo!, Amaenaide yo!! Katsu!! and more recent ones such as Asu no Yoichi and Tayutama -Kiss on my Deity- and many, many, many more. To Heart 2 is one of the most generic anime you can find. Never quite understood ecchi, either make a hentai or make real anime don't try to hybrid. In truth Harem is probably the worst genre of anime, well maybe after ecchi. You see, it is really bad, but then again so are almost all of the anime this anime try to look like. I don't really know if I actually want to write a Most likely I watched it because I've been watching some good anime lately and I decided it's time for some balance. Maybe it's because I watched the original To Heart which was bad and I wanted to relive sitting through incredibly agonizing episodes filled with generic story, characters and screenplay. Why did I watch this? Why did I decide on writing a review when it is clear it is at the bottom of the ladder that all anime try to climb. Advisory Panel: Astra Zeneca Bayer Cipla, Eli Lilly Fortbildungskolleg Novo Nordisk Pfizer Sanofi Bayer Roche Eyesense.One can ask oneself the simple question why? TF has the following conflicts of interest: Speaker Panel: Abbott Astra Zeneca Böhringer Ingelheim, Berlin Chemie Cipla, Eli Lilly Fortbildungskolleg MSD Novartis, Novo Nordisk Sanofi. ![]() He received honoraria from: Bayer Health Care Astra-Zeneca Medtronic ResMed Boehringer Ingelheim Rigel Sanofi Aventis Pfizer Janssen-Cilag Novartis Bristol Myers Squib Thoratec Abiomed Daiichi Sankyo Abbott Cardiac Dimensions. AZ has acted as consultant for: Bayer Health Care Boehringer Ingelheim Rigel Cardiorentis Medscape Stealth Peptides Sanofi Aventis Medtronic Novartis. ALB has lectured for Amgen, AstraZeneca, Lilly, Boehringer Ingelheim, NovoNordisc, and MSD, and served as a consultant for Böhringer Ingelheim, AstraZeneca, and NovoNordisk. ![]() ![]() NM has lectured for Amgen, Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, Lilly, NovoNordisk NM has conducted research projects supported by Boehringer Ingelheim and MSD and has acted as consultant to Amgen, Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, NovoNordisk, Lilly and Bayer. DMW has lectured and advised Amgen, AstraZeneca, Boehringer Ingelheim, MSD, NovoNordisk and Sanofi-Aventis. KS also carried out a research project supported by Boehringer Ingelheim. ![]() KS has lectured for Amgen, AstraZeneca, Bayer, OmniaMed, Lilly, Boehringer Ingelheim, Novartis, NovoNordisc and MSD and acted as consultant to AstraZeneca, Amgen, Böhringer Ingelheim and Lilly. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |